Key result
SB 209670, a potent nonpeptide endothelin receptor antagonist, produced a 52% reduction in neointima formation following balloon angioplasty in rats.
SB 209670 is a potent, rationally designed non-peptide endothelin receptor antagonist that demonstrates physiological efficacy in preclinical models of hypertension, stroke, and vascular injury.
Answers are grounded in this paper and cite their sources.
Requires human trials before clinical use; leaves open therapeutic potential of endothelin antagonism in hypertension and stroke.
An extremely potent and highly specific non-peptide, subnanomolar endothelin (ET) receptor antagonist, SB 209670, has been synthesized and characterized. SB 209670, which was rationally designed using conformational models of ET-1, selectively inhibits binding of 125I-labeled ET-1 to cloned human ET receptor subtypes ETA and ETB (Ki = 0.2 and 18 nM, respectively). SB 209670 produces concentration-dependent inhibition of ET-1-mediated vasoconstriction in isolated vascular tissues and in vivo following either intravenous or intraduodenal administration. SB 209670 produces a dose-dependent reduction in blood pressure in hypertensive rats, protects from ischemia-induced neuronal degeneration in a gerbil stroke model, and attenuates neointima formation following rat carotid artery balloon angioplasty. SB 209670 will be useful in characterizing and classifying the physiological and pathophysiological effects of ET.
No takes yet. Share an insight, caveat, or question.
Ohlstein et al. (1994) studied Preclinical models of cardiovascular disease and stroke. SB 209670 vs. Vehicle was evaluated on Neointima formation following balloon angioplasty (52% reduction, p=<0.05). SB 209670, a potent nonpeptide endothelin receptor antagonist, produced a 52% reduction in neointima formation following balloon angioplasty in rats.
Synapse has enriched 10 related papers. Consider them for comparative context: